ANT-GROUP
16.6.2022 05:03:07 CEST | Business Wire | Press release
Ant Group today announced the launch of Alipay+ Unified Payment. This major product upgrade provides a unified, scalable technical solution to help online and brick-and-mortar merchants collect money through all digital payment methods supported by Alipay+ in a more convenient and effective way.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006164/en/
Alipay+ offers a suite of innovative cross-border digital payments and marketing solutions, enabling merchants, especially small and medium-sized businesses, to better serve consumers worldwide. With this upgrade, Alipay+ Unified Payment further helps merchants directly reach over one billion consumers by making it easier for them to pay. Going forward, digital payment users in different countries can make cross-border payment with their local currencies wherever they see an Alipay+ sign, either online or offline, if the mobile payment methods they use adopt Alipay+ solutions.
After online merchants integrate Alipay+ Unified Payment, consumers will see an Alipay+ option when they make payments in their cashier pages. Cashiers will present users who choose to pay through Alipay+ recommended digital payment methods it supports based on their countries and payment preferences. Users can then proceed with paying using their preferred digital payment method. Brick-and-mortar merchants integrate Alipay+ Unified Payment by adopting a unified QR code scheme and scan-to-pay services, which can accept all digital payment methods enabled by Alipay+.
Alipay+ Unified Payment brings merchants highly efficient and cost-optimized digitalized cashier experiences. After one-time integration, merchants can accept all available digital payment methods, including existing methods and ones to be introduced by Alipay+ later on. Moreover, with innovative and digital-native technologies, Alipay+ can be integrated into merchants’ own systems with a simple technical adaption. Alipay+ Unified Payment also provides marketing services as part of its cashier solutions to help merchants expand the reach of targeted potential users.
Alipay+ Unified Payment began its pilot phase in May 2022. Merchants, including Buygogo, an e-commerce platform and Smile.one, one of the leading top-up services for online games and entertainment, have participated in the pilot program.
“We’re excited to launch Alipay+ Unified Payment, a one-stop solution integrating a wide range of digital payment methods. This upgrade helps merchants handle digital payments more conveniently and seamlessly, and greatly improves their operating efficiency,” said Cheng Guoming, General Manager of Alipay+ Global Partnership, Ant Group. “We are dedicated to leveraging our innovative products and technologies to better serve merchants around the world and facilitating even more cross-border business activities as the global economy recovers from the pandemic.”
About Alipay+
Alipay+ provides global cross-border digital payments and marketing solutions that enable global e-wallets and merchant partners, especially small and medium-sized businesses, to better serve their users and customers.
Alipay+ is introduced by Ant Group, the owner and operator of Alipay. As one of the world’s leading digital payment platforms, Alipay serves hundreds of millions of users by connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615006164/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom